now want continued to thank here strong in continuing to set support out well where employees into is with from the we today working a journey as nicely look it which our who appreciate also have for are and us of you core to business, global to the platform. as the in smooth and very ensure of strength but different this to onwards. capacity. I'm build future, we a I Thanks, helped while transition Scott. our Viatris forward the opportunity up you with I pleased as take stability growth look all
results. Moving to our Commercial segment
as quarter reaffirms that year-over-year top operational we standing consecutive line and further growth of We strong set have future. which a delivered the we are predicted, for up second
This with the we year year-over-year X% and expectations. well end our line operational in growth full to are recorded positioned quarter,
well-balanced an of of seventh developed strong quarter Our it X% versus year-over-year the operationally. business markets basis, delivered prior X% another on grew making growth. consecutive quarter, year-over-year Europe year growing the operational
the in Italy A led contributing in growth Europe generics solid and was factor. France the the of performance another region.
line operational North Our America was in basis, with expectations. business year-over-year on an our X% up
expectations. Breyna, better and the vancomycin [indiscernible] other launches contribution for as including portfolio Our performed Symbicort, better acetate, glatiramer generics of performed the new generic than driven Xulane expected, Also, continued some lenalidomide. by products, than and such key
supported that segment we Our market. our brand year the Yupelri, which over market remain demand by grew full and this business in developed quarter Overall, X% the confident last was will strong the epinephrine in expectations. year meet
Emerging growth. generics and This another had and Markets deliver geographies. like led year-over-year from portfolio stronger-than-expected strong Turkey to growth strength quarter segment well Effexor. brands our X% delivered broader operational were Lyrica, year-over-year performance by across Asia Emerging mid-single-digit positioned solid-performing is and and Zoloft
customer while generics due JANZ, performed where to buying our were slightly patterns. with brands to expectations below line Moving expectations, in primarily
to full perform year, driven China. retail by Greater this line be prior flat channel the We on year. China than better full strong We expectations. primarily with expectations Greater deliver in expectations. quarter, track our segment continue performance was China the experienced our believe to solid will of to that in year for another slightly
our on our we XX to China, NDA we our progress also of made to positive We III received Phase currently We our recently China. products in in data, forward and pipeline clinical results authority report is mid-'XX. U.S. under happy review for submitting steady line health which I'm trials this region. consistent Yupelri look have other with clinical in top
saw quarter. continue Tyrvaya, first for almost to Eye early quarter to [indiscernible] we prescription X our focus the Care by into in X% [indiscernible] Division marketing future, in growth Moving supported October. which in direct-to-consumer this We'll campaign the launched growth on and we
deliver are product million than new launches on $XXX track full year-to-date to from recorded have new revenue million product We the for $XXX in year. and more revenue of
for pipeline. some discuss key now me Let updates our R&D
pipeline, acetate by the the on Ryzumvi of a track, Eye in [indiscernible]. the updates, received range of with and All vision-related mydriasis care remain programs that for pipeline looking the a approval are we commercial 'XX. aimed development reversal are disorders. beginning for is other are Care to at the continued glatiramer pharmacologically-induced in FDA of Switching of progress to addressing We our we forward eye first excited and which pleased U.S. launch half
As it March assigned you had X, and review for our FDA the PDUFA of date a accepted recall, XXXX. NDA
our by saddened FDA we the situation working make we partner, steady to remains of While NDA, closely operational. very we fully progress the Israel, Mapi, in are are our with who review regarding tragic continue and
in potential excited Europe are We about this in bring have recently and our submitted the opportunity to product Europe. patients to registration
batches from way the drug completed our characterization, on our Our manufacturing and drug of is of program Botox by manufacturing. progressing recently well product development, IND remain validation are this track to product of our year. We We drug the drug file the on and prospective. biosimilar substance end IND-enabling to well the substance complete
We in studies this XXXX. expect of to program pivotal half clinical first the initiate the for
opioid-sparing late this remains initiate we on an have Xulane the acceleration in Also, December. we for study FDA III rate are product with U.S. for interacting December. expect this program our in from III our enroll our study. closely in the We Phase to now last Phase Our enrollment for low-dose novel program track, benefited and patient meloxicam to
of the for we filing to in target III disorder study and our generalized continues half Our in progress submit Phase on NDA to first the schedule, to Effexor, anxiety according remain XXXX. Japan,
$X With Finally, I to planned, about continue complex this of Sanjeev. and the hand call franchise. over of very we will ahead moving be our all important programs as billion to the potential excited are potential injectable that,
